Moderna (mRNA Vaccine) for COVID-19: A Leap in Vaccine World

Anita Rani Bhatia, A. Saxena, N. Tyagi, Peyir Bagra, P. Bhatia
{"title":"Moderna (mRNA Vaccine) for COVID-19: A Leap in Vaccine World","authors":"Anita Rani Bhatia, A. Saxena, N. Tyagi, Peyir Bagra, P. Bhatia","doi":"10.18502/pbr.v8i1.9391","DOIUrl":null,"url":null,"abstract":"\n \n \n \nIn December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) appeared and spread worldwide, triggering a pandemic of respiratory illness. So, there was an urgent need for vaccines worldwide. The mRNA-based vaccines are undergoing an accelerated phase of development during this pandemic. WHO has issued interim guidelines for administering the Moderna mRNA-1273 vaccine against COVID-19 based on advice given by the Strategic Advisory Group of Experts on Immunization (SAGE). The significant future directions for study would be comparing and elucidating the immune processes triggered by mRNA vaccine platforms, developing existing methods focused on these mechanisms, and introducing new clinical trials of these vaccines against additional disease targets. \nThis study aims to reveal the important role and contribution of the Moderna mRNA-1273 vaccine to COVID-19 vaccinology. \nModerna mRNA-1273 vaccine could be the keystone of modern vaccinology in the context of the COVID-19 pandemic. \n \n \n \n","PeriodicalId":6323,"journal":{"name":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"2005 Asian Conference on Sensors and the International Conference on New Techniques in Pharmaceutical and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/pbr.v8i1.9391","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) appeared and spread worldwide, triggering a pandemic of respiratory illness. So, there was an urgent need for vaccines worldwide. The mRNA-based vaccines are undergoing an accelerated phase of development during this pandemic. WHO has issued interim guidelines for administering the Moderna mRNA-1273 vaccine against COVID-19 based on advice given by the Strategic Advisory Group of Experts on Immunization (SAGE). The significant future directions for study would be comparing and elucidating the immune processes triggered by mRNA vaccine platforms, developing existing methods focused on these mechanisms, and introducing new clinical trials of these vaccines against additional disease targets. This study aims to reveal the important role and contribution of the Moderna mRNA-1273 vaccine to COVID-19 vaccinology. Moderna mRNA-1273 vaccine could be the keystone of modern vaccinology in the context of the COVID-19 pandemic.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19的Moderna (mRNA疫苗):疫苗世界的飞跃
2019年12月,严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)出现并在全球传播,引发了一场呼吸系统疾病大流行。因此,全世界都迫切需要疫苗。在本次大流行期间,基于mrna的疫苗正处于加速开发阶段。世卫组织根据免疫战略咨询专家组提供的建议,发布了针对COVID-19的Moderna mRNA-1273疫苗管理临时指南。未来重要的研究方向将是比较和阐明mRNA疫苗平台触发的免疫过程,开发专注于这些机制的现有方法,并引入这些疫苗针对其他疾病靶点的新临床试验。本研究旨在揭示Moderna mRNA-1273疫苗在COVID-19疫苗学中的重要作用和贡献。在新冠肺炎大流行背景下,现代mRNA-1273疫苗可能成为现代疫苗学的基石。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antibacterial Activities and Chemical Compounds of Plantago lanceolata (Ribwort Plantain) and Plantago major (Broadleaf Plantain) Leaf Extracts Effectiveness of 5-aminolevulinic Acid-mediated Photodynamic Therapy Combined With Curcumin Drug-related Problems Among Type 2 Diabetic Patients With Hypertension in a Tertiary Care Hospital in Lebanon: A Cross-sectional Study The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial Acetylcholinesterase Inhibitory Activity of Standardized Cannabinoids-rich Fractions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1